– USA, CA – Estrella Immunopharma, Inc. (NASDAQ: ESLA /ESLAW), a clinical-stage biopharmaceutical company, announced the appointment of Hong Zhang to its Board of Directors as Chairperson, increasing the Board to six members.
Dr. Cheng Liu, CEO and previous Chairman, will continue to serve on the Board of Directors.
About Hong Zhang
Ms. Hong Zhang is a highly accomplished executive with over 25 years of experience in financial and corporate strategy. Most recently, she served as VP at Incinta Medical Group Ltd., where she played a key role in establishing the company’s strong financial position and growth. Before that, Ms. Zhang simultaneously served as the Chairperson at Beijing Ocean Co-stone Capital Investment Management Company, and as Managing Director at Shenzhen Co-stone Venture Investment Management Company and oversaw fund management, risk control, and investment. Earlier in her career, she held the position of VP at UOB Investment (China) Ltd., a private equity company. Ms. Zhang began her career in the legal division of Shandong High-Tech Investment Corporation Co. Ltd., a venture capital firm, working as a management counsel.
In addition to her role at Estrella, Ms. Zhang currently has ownership of and serves on the board of Co-Fame Investment Management Co. Ltd.
Ms. Zhang holds a Bachelor of Laws degree from Shandong University and a Postgraduate degree in Law from China University of Political Science and Law.
About Estrella Immunopharma
Estrella is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Estrella’s mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and other diseases. To accomplish this mission, Estrella’s lead product candidate, EB103, utilizes Eureka’s ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. Estrella is also developing EB104, which also utilizes Eureka’s ARTEMIS technology to target not only CD19 but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies.
For more information : https://www.estrellabio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.